Last updated: August 9, 2026
PEG-20 sorbitan oleate, commonly identified as polysorbate 80 or Tween 80, is a high-volume, low-dose nonionic surfactant used in biologics, vaccines, injectable formulations, ophthalmic products, oral medicines, cosmetics, and food applications. Its market outlook is supported by growth in protein therapeutics and complex injectable products, but pricing power is limited by multiple qualified suppliers and the availability of related polysorbates. Public companies do not report revenue for PEG-20 sorbitan oleate as a standalone product, so its financial trajectory must be assessed through demand drivers, manufacturing economics, regulatory requirements, and supplier disclosures.
What is PEG-20 sorbitan oleate?
PEG-20 sorbitan oleate is a polyoxyethylene sorbitan monooleate surfactant. It is commonly sold under the names polysorbate 80, PS80, and Tween 80. The CAS Registry Number is 9005-65-6.
The material is manufactured by esterifying sorbitan with oleic acid and subsequently adding approximately 20 ethylene oxide units. Commercial material is a mixture rather than a single molecular species. Its composition can vary according to raw-material source, ethoxylation profile, oleic-acid composition, water content, peroxide level, and other quality attributes.
| Attribute |
Information |
| Common name |
Polysorbate 80 |
| Alternative name |
PEG-20 sorbitan oleate |
| CAS number |
9005-65-6 |
| Chemical class |
Nonionic surfactant |
| Primary function |
Solubilizer, emulsifier, wetting agent, protein-stabilizing excipient |
| Common pharmaceutical grades |
Compendial, GMP, low-peroxide, low-particulate, biologic-grade |
| Main dosage forms |
Injectable, ophthalmic, oral liquid, topical, vaccine |
| Principal risk attributes |
Oxidation, hydrolysis, peroxide formation, fatty-acid variability, particulates |
| Major alternatives |
Polysorbate 20, poloxamers, sucrose esters, lecithin, albumin, selected lipid excipients |
FDA’s Inactive Ingredient Database includes polysorbate 80 across multiple routes and dosage forms. The United States Pharmacopeia and European Pharmacopoeia also recognize quality standards for polysorbate 80 and related excipients.[1][2]
How large is the PEG-20 sorbitan oleate market?
No authoritative public source reports the global revenue of PEG-20 sorbitan oleate separately from the wider polysorbate, pharmaceutical excipient, or specialty surfactant markets. Commercial market reports generally combine polysorbate 80 with other polysorbates, surfactants, emulsifiers, or excipients. Those estimates should not be treated as audited market data for PEG-20 sorbitan oleate.
The addressable market has two distinct segments:
- High-volume industrial, food, and personal-care polysorbate 80.
- Higher-value pharmaceutical and biopharmaceutical grades.
Pharmaceutical material represents a smaller volume share than industrial and consumer applications but commands higher pricing because customers require batch traceability, compendial compliance, extractables and leachables documentation, elemental impurity controls, bioburden control, and validated change management.
The commercial value of a pharmaceutical-grade unit is therefore determined less by the raw surfactant content than by:
- GMP manufacturing and packaging;
- documentation and regulatory support;
- peroxide and aldehyde control;
- lot-to-lot consistency;
- supply continuity;
- customer qualification status;
- compatibility with biologic drug products.
What is driving demand for polysorbate 80?
How do biologics affect demand?
Biologics are the principal pharmaceutical growth driver. Monoclonal antibodies, recombinant proteins, vaccines, viral-vector products, and some gene-therapy formulations use polysorbates to reduce interfacial stress and limit protein adsorption or aggregation.
The material is often used at low concentrations, commonly in the approximate range of 0.01% to 0.1%, although the level varies by product and formulation. This creates a market with modest volume consumption per dose but high qualification value. Once included in a commercial biologic, the excipient becomes embedded in the product’s formulation, analytical methods, stability program, and regulatory filings.
The number of biologic approvals has expanded over the past decade, and FDA continues to identify complex biologics and biosimilars as a major part of the pharmaceutical pipeline.[3] This supports recurring demand for pharmaceutical-grade polysorbate 80 even when individual product volumes are small.
Which non-pharmaceutical sectors support demand?
Personal-care products, cosmetics, food emulsions, veterinary products, and industrial formulations provide broader volume support. These sectors are generally more price-sensitive and can use material with specifications that are less demanding than injectable-grade excipient requirements.
This segmentation reduces dependence on any single pharmaceutical customer. It also limits price expansion because pharmaceutical suppliers compete with large-volume commodity producers and alternative nonionic surfactants.
Which companies supply PEG-20 sorbitan oleate?
The supply base includes specialty excipient manufacturers, oleochemical companies, and distributors. Supplier participation varies by grade and region.
| Supplier group |
Typical market position |
| Croda |
Pharmaceutical and biopharmaceutical excipients, including surfactants and formulation materials |
| BASF |
Broad specialty chemicals and pharmaceutical excipient portfolio |
| NOF Corporation |
Pharmaceutical-grade surfactants and lipid-related materials |
| Evonik |
Specialty excipients and formulation technologies, including alternatives to conventional surfactants |
| Spectrum Chemical and regional distributors |
Distribution, repackaging, and laboratory or small-scale supply |
| Large contract manufacturers and regional chemical producers |
Industrial, food, cosmetic, and selected pharmaceutical grades |
Croda markets pharmaceutical excipients under its Super Refined and related product families. BASF markets pharmaceutical excipients through its Soluplus, Kolliphor, and other formulation-material portfolios. NOF supplies pharmaceutical surfactants and lipid-based excipients. Product names and available grades differ by geography and application.[4][5][6]
Supplier qualification is a meaningful competitive barrier. A drug company may spend months or years qualifying an excipient supplier, validating analytical methods, and assessing formulation performance. This creates switching friction even when the underlying chemical is available from several manufacturers.
How does manufacturing affect the financial trajectory?
The manufacturing process is mature, but pharmaceutical-grade production is not a simple commodity operation. Key cost variables include:
- sorbitan and oleic-acid input costs;
- ethylene oxide pricing and availability;
- energy and utilities;
- purification and filtration;
- analytical testing;
- packaging and controlled storage;
- rejected or reprocessed batches;
- regulatory change-control obligations.
Ethylene oxide is a strategically important input. Supply disruptions, plant outages, transportation restrictions, or changes in chemical-plant regulation can affect production economics. Oleic acid introduces another variable because its fatty-acid composition can differ by source and processing route.
For pharmaceutical grades, oxidation control is particularly important. Polysorbate 80 can undergo hydrolysis and oxidation, producing fatty acids, peroxides, aldehydes, and other degradation products. These species can affect protein stability and may contribute to particulate formation in sensitive formulations.[7]
The financial consequence is a widening spread between standard-grade and biologic-grade material. Producers that can demonstrate low peroxide content, improved stability, and consistent impurity profiles may protect margins better than suppliers selling only standard polysorbate 80.
What regulatory status applies to PEG-20 sorbitan oleate?
Polysorbate 80 is an established excipient with broad regulatory use. It is listed in FDA’s Inactive Ingredient Database for approved products and is recognized in major pharmacopeias. Its use in a specific drug product still requires product-specific justification, compatibility data, toxicological assessment, manufacturing controls, and stability evidence.
FDA and Orange Book status
Polysorbate 80 is not an active pharmaceutical ingredient and does not have a standalone FDA Orange Book listing. The Orange Book identifies approved drug products and associated patents or exclusivities, not independent excipient ownership.
An excipient supplier therefore does not obtain Orange Book exclusivity for the chemical itself. Any commercial protection usually arises from:
- proprietary purification or stabilization processes;
- controlled impurity specifications;
- manufacturing know-how;
- customer qualification;
- trademarks and product branding;
- formulation patents owned by drug-product developers.
European and global requirements
European pharmaceutical users typically rely on European Pharmacopoeia compliance, ICH quality principles, GMP controls, and product-specific regulatory filings. China, Japan, and other jurisdictions apply their own excipient registration or documentation requirements.
For biologics, regulators increasingly expect characterization of surfactant degradation, visible and subvisible particles, extractables, leachables, and interaction with the active ingredient. EMA and FDA guidance on biologic quality and pharmaceutical development supports a risk-based approach to excipient selection and control.[8][9]
What patents protect polysorbate 80?
The chemical identity of PEG-20 sorbitan oleate is old and widely disclosed. Broad composition-of-matter patent protection for polysorbate 80 is not the principal commercial barrier.
Relevant intellectual-property protection is more likely to cover:
- low-peroxide polysorbate compositions;
- stabilized polysorbate formulations;
- oxidation-resistant excipient systems;
- manufacturing or purification processes;
- combinations with specific biologics;
- container and closure systems;
- methods for reducing particles or degradation products.
Drug-product patents may claim a specific antibody or biologic formulation containing polysorbate 80. Those claims protect the finished medicine, not the excipient market as a standalone product.
Are Paragraph IV challenges relevant?
Paragraph IV litigation generally concerns an abbreviated new drug application challenging patents listed for an approved drug. It does not ordinarily apply to the sale of polysorbate 80 as an excipient.
A Paragraph IV dispute could become relevant indirectly if a generic applicant challenges a drug formulation patent that claims polysorbate 80, a related surfactant, or a specific concentration range. The economic exposure would belong to the drug-product patent holder rather than the excipient manufacturer.
What formulation risks could constrain demand?
Polysorbate 80 has strong market penetration, but formulation scientists are assessing alternatives because of degradation and particle concerns. The principal technical risks are:
- oxidation during storage;
- hydrolysis of ester bonds;
- formation of free fatty acids;
- peroxide-mediated protein oxidation;
- subvisible particle generation;
- interaction with container surfaces;
- variability between lots and suppliers.
Polysorbate 20 is a close substitute in some formulations, but it is not interchangeable in every biologic. Poloxamer 188, poloxamer 407, sucrose esters, and other surfactants can replace polysorbate 80 in selected products, subject to compatibility and regulatory evaluation.
The replacement risk is therefore gradual rather than immediate. Once a biologic is commercialized with polysorbate 80, switching excipients can require comparability studies, stability work, process changes, and regulatory submissions. New products have greater flexibility to adopt alternatives.
How strong is the supplier patent estate?
The standalone patent estate for polysorbate 80 is weaker than the commercial position created by manufacturing know-how and qualification status. The most defensible supplier assets are usually:
- manufacturing consistency;
- low-peroxide or low-impurity grades;
- proprietary analytical methods;
- validated global supply chains;
- regulatory files and customer history;
- technical support for biologic formulation development.
This is a process-and-qualification market rather than a classic molecule-patent market. Barriers are operational and regulatory, not primarily based on exclusivity periods.
What licensing deals and litigation affect the market?
Public licensing activity specific to PEG-20 sorbitan oleate is limited. The excipient is generally purchased through supply agreements, distributor contracts, quality agreements, and long-term sourcing arrangements rather than royalty-bearing licenses.
Public litigation directly concerning the standalone sale of polysorbate 80 is also limited relative to litigation involving active pharmaceutical ingredients, biologic formulations, and delivery systems. Disputes are more likely to concern:
- supply interruption;
- batch quality;
- specification compliance;
- contamination;
- change control;
- product liability;
- formulation patents for the finished drug.
No standalone Orange Book exclusivity or conventional generic-entry event defines the market.
What is the financial outlook for PEG-20 sorbitan oleate?
The financial trajectory is likely to show moderate volume growth and stronger value growth in pharmaceutical and biologic grades. The main scenarios are:
| Scenario |
Market effect |
| Biologics growth continues |
Higher demand for GMP and low-peroxide grades |
| More biosimilars enter the market |
Greater demand, but stronger purchasing pressure and price competition |
| Polysorbate degradation concerns increase |
Premium for stabilized grades; gradual substitution risk |
| Ethylene oxide or oleochemical costs rise |
Margin pressure and contract repricing |
| Supplier consolidation occurs |
Better utilization and possible pricing discipline |
| New surfactant alternatives gain adoption |
Reduced long-term share in selected biologic formulations |
Biosimilar expansion is commercially mixed. It increases the number of products using established excipients, but biosimilar developers typically pursue lower manufacturing costs and may negotiate aggressively with suppliers. The result is greater demand without a corresponding guarantee of higher unit prices.
Revenue exposure for large suppliers is difficult to quantify because polysorbate 80 is bundled into broader excipient and specialty-chemical reporting. Investors should track pharmaceutical excipient growth, biologics production, plant investment, capacity utilization, raw-material costs, and commentary on high-purity or biopharmaceutical materials rather than rely on standalone polysorbate 80 revenue estimates.
What generic-entry risks exist for polysorbate 80?
Polysorbate 80 has no conventional generic-entry cliff because it is an excipient rather than a patented drug. The main competitive risks are:
- substitution by polysorbate 20 or poloxamers;
- in-house qualification of alternative suppliers;
- customer dual-sourcing;
- procurement-led price reductions;
- movement from branded grades to compendial equivalents;
- formulation redesign for oxidation control.
The main commercial defense is integration into customer development and quality systems. Suppliers that enter early-stage biologic development and remain qualified through commercial launch are less exposed to short-term price competition.
Key Takeaways
- PEG-20 sorbitan oleate is commonly known as polysorbate 80 or Tween 80.
- Pharmaceutical demand is linked closely to biologics, vaccines, injectables, and ophthalmic products.
- No reliable public source reports standalone global revenue for the excipient.
- Pharmaceutical-grade material has higher value because of GMP, impurity, oxidation, and documentation requirements.
- The chemical has limited standalone patent exclusivity; supplier advantage comes from process control, quality data, and customer qualification.
- FDA Orange Book and Paragraph IV mechanisms generally apply only indirectly through finished drug formulations.
- Oxidation, hydrolysis, peroxide formation, and particle generation are the main technical risks.
- Biosimilar growth should increase demand while intensifying procurement pressure.
- Long-term substitution risk exists, but switching excipients in approved biologics is costly and slow.
- Financial performance is best assessed through supplier-level excipient disclosures and biologics-market indicators, not standalone polysorbate 80 revenue estimates.
FAQs
Is PEG-20 sorbitan oleate the same as polysorbate 80?
Yes. PEG-20 sorbitan oleate is a commonly used chemical description for polysorbate 80, although commercial products are mixtures with variable composition.
Is polysorbate 80 safe in injectable medicines?
Polysorbate 80 has a long history of use in approved pharmaceutical products. Safety and suitability remain dependent on concentration, route of administration, product formulation, impurity profile, and product-specific regulatory review.
Can polysorbate 20 replace polysorbate 80?
Sometimes. The two excipients differ in fatty-acid composition and can produce different effects on protein stability, oxidation, particles, and container interactions. Replacement requires formulation and comparability testing.
Does polysorbate 80 have a patent expiration date?
The core chemical is an established, widely disclosed excipient and does not have a single commercially controlling patent expiration date. Specific stabilized grades, manufacturing methods, and drug formulations may have separate patent terms.
Which quality attribute is most important for biologic formulations?
No single attribute controls every product. Peroxide level, oxidation products, fatty-acid composition, hydrolysis profile, particle generation, and lot-to-lot consistency are among the most important attributes for biologic applications.
References
- U.S. Food and Drug Administration. (n.d.). Inactive Ingredient Database. https://www.accessdata.fda.gov/scripts/cder/iig/index.cfm
- United States Pharmacopeia. (2024). USP-NF monograph: Polysorbate 80. United States Pharmacopeial Convention.
- U.S. Food and Drug Administration. (2024). Biosimilar product information. https://www.fda.gov/drugs/biosimilars
- Croda International Plc. (2024). Annual report and accounts 2023. https://www.croda.com
- BASF SE. (2024). Annual report 2023. https://www.basf.com
- NOF Corporation. (2024). Integrated report 2024. https://www.nof.co.jp
- Hawe, A., Frieß, W., Sutter, M., & Jiskoot, W. (2008). Bovine serum albumin (BSA) as a model protein for the optimization of biopharmaceutical formulations. Journal of Pharmaceutical Sciences, 97(12), 5119-5134.
- European Medicines Agency. (2018). Guideline on development, production, characterisation and specifications for monoclonal antibodies and related products. https://www.ema.europa.eu
- U.S. Food and Drug Administration. (2004). Guidance for industry: PAT, a framework for innovative pharmaceutical development, manufacturing, and quality assurance. https://www.fda.gov-regulatory-information/search-fda-guidance-documents/pat-framework-innovative-pharmaceutical-development-manufacturing-and-quality-assurance
